2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2241

Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2281

Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2320

Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years

ARHP Pediatric Rheumatology – Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2672

Perceived Barriers to Mental Health Care Among Patients with Systemic Sclerosis: A Qualitative Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2056

Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2694

Performance of Patient-Reported Outcomes Measurement Information Systems (PROMIS) Promis-29 and Promis Self-Efficacy in Systemic Sclerosis (SSc)

ARHP Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster

9:00AM-11:00AM: Abstract Number: 2565

Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2193

Physical Activity and Disease Progression in Persons with or at Higher Risk for Knee Osteoarthritis

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2013

Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2092

Pilot Clinical Study of a Novel Unobtrusive Carpal Tunnel Tissue Manipulation Device in Reducing Symptoms of Carpal Tunnel Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2708

Placental Growth Factor Regulates the Generation of T-Helper 17 Cells to Link Angiogenesis with Autoimmunity

T Cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2600

Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2690

Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2338

Plasma Exosomes from Children with Juvenile Dermatomyositis Are Taken up By Human Aortic Endothelial Cells and Are Associated with Altered Gene Expression in Those Cells

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2606

Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].